[9] As per Forbes list of India’s 100 richest tycoons, dated OCTOBER 09, 2024, Hasmukh Chudgar & family is ranked 35th with a net worth of $8.2 Billion.

[13] In 2015, the company launched its first biosimilar product, Filgrastim in Europe, to treat patients with advanced HIV infection and immune system disorders such as neutropenia.

[14][15] Apart from EU GMP certification, the company has approvals from MCC South Africa, Gulf Cooperation Council (GCC), Syria, Yemen, Belarus and several other national health authorities for its manufacturing facility and products.

[21] In 2018, Intas' subsidiary Accord Healthcare reopened Sanofi's Fawdon plant in the UK for manufacturing generic effervescent medicines.

[24] In December 2022, upon compliance inspection by the FDA, Intas plant in Sanand was found to be in violation of multiple laboratory practices and protocols, as revealed in a report from January 2023.

[25] Testing conducted on behalf of the American military by the laboratory Valisure revealed that generic tacrolimus manufactured by Intas was not a functional substitute for the brand name drug.